HPQ Silicon Confirms Completion and Shipment of First Industrial Batches of HPQ ENDURA+ Battery Cells

Executive Summary

• HPQ Silicon announced completion of its first industrial batches of high‑performance lithium‑ion cells (18650 4,000 mAh and 21700 6,000 mAh) using GEN3 silicon anodes, now en route to Montreal for customer evaluation.
• The company confirms finalized product specification sheets and highlights the cells’ superior energy density (up to 4,000 mAh/18650) and cycle life (≈1,000 cycles) versus market averages.
• HPQ’s Board extended the exercise date of 2,107,318 outstanding share purchase warrants (originally priced at $0.30) to November 23 2027, pending TSX‑V exchange approval.

Key Details

• Industrial Batch Shipment – First commercial‑scale production run of HPQ ENDURA+ cells completed; shipments include both 18650 and 21700 formats.
• Cell Specifications – 18650: 4,000 mAh, ≥1,000 charge cycles; 21700: 6,000 mAh, ≥1,000 charge cycles. Data sheets now publicly available.
• Manufacturing Partner – Production subcontracted to an established large‑scale battery manufacturer (name confidential) enabling high‑throughput output without new capital investment.
• Capacity Outlook – Aligns with HPQ’s prior projection of up to 1.5 million cells annually through its partnership with Novacium SAS.
• Market Positioning – Compared to typical market cells (2,500–3,500 mAh, <500 cycles, $4.50‑$8.00 per cell), HPQ’s ENDURA+ offers higher energy density and longer life at comparable price points, targeting mobility, electronics, defense, and telecom sectors in North America.
• Customer Engagement – Batches will be used in direct discussions with prospective clients across multiple industries to demonstrate performance and accelerate commercial adoption.
• Warrants Extension – Board resolution (Sept 17 2025) extends exercise date of 2,107,318 share purchase warrants (1,125,500 expiring Nov 17 2025; 981,818 expiring Nov 23 2025) to Nov 23 2027. Exercise price remains $0.30 per share. No exercises in the past six months. Extension subject to TSX‑V and regulatory approvals.
• Forward‑Looking Statements – Management reiterates expectations for continued manufacturing scale‑up, prototype testing, financing activities, and market positioning; acknowledges typical risks.

Notable Quotes

“These first shipments demonstrate our ability to execute and move swiftly from R&D to commercial readiness… We are now in a position to put our batteries in front of customers, backed by real performance data and a clear path to scaled production.” – Bernard J. Tourillon, Chairman, President & CEO

Materiality Assessment: Material – Positive (significant commercial production milestone and potential revenue generation; warrants extension may affect shareholder equity but is routine.)